220 related articles for article (PubMed ID: 33481696)
1. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
Inagaki T; Pearson JT; Tsuchimochi H; Schwenke DO; Saito S; Higuchi T; Masaki T; Umetani K; Shirai M; Nakaoka Y
Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1021-H1036. PubMed ID: 33481696
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
[TBL] [Abstract][Full Text] [Related]
3. Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure.
Suen CM; Chaudhary KR; Deng Y; Jiang B; Stewart DJ
Cardiovasc Res; 2019 Mar; 115(4):788-799. PubMed ID: 30357319
[TBL] [Abstract][Full Text] [Related]
4. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
[TBL] [Abstract][Full Text] [Related]
5. Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.
Drozd K; Ahmadi A; Deng Y; Jiang B; Petryk J; Thorn S; Stewart D; Beanlands R; deKemp RA; DaSilva JN; Mielniczuk LM
J Nucl Cardiol; 2017 Dec; 24(6):1979-1989. PubMed ID: 27688036
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
[TBL] [Abstract][Full Text] [Related]
7. Identification of Celastrol as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).
Kurosawa R; Satoh K; Nakata T; Shindo T; Kikuchi N; Satoh T; Siddique MAH; Omura J; Sunamura S; Nogi M; Takeuchi Y; Miyata S; Shimokawa H
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1205-1217. PubMed ID: 33472404
[TBL] [Abstract][Full Text] [Related]
8. Impaired NO-mediated vasodilation with increased superoxide but robust EDHF function in right ventricular arterial microvessels of pulmonary hypertensive rats.
Kajiya M; Hirota M; Inai Y; Kiyooka T; Morimoto T; Iwasaki T; Endo K; Mohri S; Shimizu J; Yada T; Ogasawara Y; Naruse K; Ohe T; Kajiya F
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2737-44. PubMed ID: 17220192
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
Lu M; Chen LY; Gairhe S; Mazer AJ; Anderson SA; Nelson JNH; Noguchi A; Siddique MAH; Dougherty EJ; Zou Y; Johnston KA; Yu ZX; Wang H; Wang S; Sun J; Solomon SB; Vanderpool RR; Solomon MA; Danner RL; Elinoff JM
Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L315-L332. PubMed ID: 35043674
[TBL] [Abstract][Full Text] [Related]
11. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
12. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.
Liu A; Schreier D; Tian L; Eickhoff JC; Wang Z; Hacker TA; Chesler NC
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H273-83. PubMed ID: 24906919
[TBL] [Abstract][Full Text] [Related]
13. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.
da Silva Gonçalves Bós D; Van Der Bruggen CEE; Kurakula K; Sun XQ; Casali KR; Casali AG; Rol N; Szulcek R; Dos Remedios C; Guignabert C; Tu L; Dorfmüller P; Humbert M; Wijnker PJM; Kuster DWD; van der Velden J; Goumans MJ; Bogaard HJ; Vonk-Noordegraaf A; de Man FS; Handoko ML
Circulation; 2018 Feb; 137(9):910-924. PubMed ID: 29167228
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function.
Philip JL; Murphy TM; Schreier DA; Stevens S; Tabima DM; Albrecht M; Frump AL; Hacker TA; Lahm T; Chesler NC
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1167-H1177. PubMed ID: 30767670
[TBL] [Abstract][Full Text] [Related]
16. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Bogaard HJ; Natarajan R; Mizuno S; Abbate A; Chang PJ; Chau VQ; Hoke NN; Kraskauskas D; Kasper M; Salloum FN; Voelkel NF
Am J Respir Crit Care Med; 2010 Sep; 182(5):652-60. PubMed ID: 20508210
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
Kosanovic D; Kojonazarov B; Luitel H; Dahal BK; Sydykov A; Cornitescu T; Janssen W; Brandes RP; Davie N; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT
Respir Res; 2011 Jun; 12(1):87. PubMed ID: 21699729
[TBL] [Abstract][Full Text] [Related]
18. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
19. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
20. Differences in the microcirculation disturbance in the right and left ventricles of neonatal rats with hypoxic pulmonary hypertension.
Yang L; Cao J; Ma J; Li M; Mu Y
Microvasc Res; 2021 May; 135():104129. PubMed ID: 33385381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
